Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.36 |
| ▸ | CTSL | P07711 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TERT | O14746 | 1/20 | 0.34 |
| ▸ | MME | P08473 | 2/20 | 0.34 |
| ▸ | ACE | P12821 | 2/20 | 0.34 |
| ▸ | CPA1 | P15085 | 2/20 | 0.34 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10718818 | 0.85 | TERT (0.43) | TERTMMEACECPA1ACE2 | |
| SCHEMBL23071543 | 0.85 | TERT (0.43) | TERTMMEACECPA1ACE2 | |
| SCHEMBL10718813 | 0.85 | TERT (0.43) | TERTMMEACECPA1ACE2 | |
| SCHEMBL23071542 | 0.85 | TERT (0.43) | TERTMMEACECPA1ACE2 | |
| SCHEMBL8526546 | 0.84 | ALDH1A1 (0.46) | ENPEPALDH1A1MMEACECPA1 | |
| SCHEMBL31174309 | 0.84 | ALDH1A1 (0.46) | ENPEPALDH1A1MMEACECPA1 | |
| SCHEMBL8526548 | 0.84 | ALDH1A1 (0.46) | ENPEPALDH1A1MMEACECPA1 | |
| SCHEMBL30272494 | 0.83 | ALDH1A1 (0.50) | ENPEPALDH1A1 | |
| SCHEMBL4099835 | 0.83 | TERT (0.40) | CTSSCTSKTERTMMEACE | |
| SCHEMBL4086885 | 0.80 | ENPEP (0.31) | ENPEPTERTDPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076285-B2 | Lysobactin amides | AICURIS GMBH & CO. KG (DE) | 2011-12-13 | — | — | US | disclosed |
| US-20090203582-A1 | LYSOBACTIN AMIDES | BAYER HEALTHCARE AG (DE) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203582-A1 | LYSOBACTIN AMIDES | AADAT, HAMP, DLST | CTSS 660/4885CTSK 1058/4885ENPEP 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.